Blood transfusions tested for in Tour
Drug testing in the forthcoming Tour de France will test for homologous blood transfusions, but not...
Drug testing in the forthcoming Tour de France will test for homologous blood transfusions, but not autologous transfusions or growth hormone, the French national anti-doping laboratory announced on Thursday. According to lab director Jacques De Ceaurriz, the much promised growth hormone test, which was used at last year's Athens Olympics, is not able to be used because of financial reasons, citing the global supply of antibodies as a major problem.
Mr De Ceaurriz said that the homologous blood transfusion test will be used for the first time at the Tour, even though it was announced as going to be used at the start of last year's Tour. The controversial transfusion test has already been used at the Athens Olympics and during the Vuelta a España in 2004, with the then Phonak teammates Tyler Hamilton and Santiago Perez both testing positive for the presence of another type of red blood cell in their bodies. Appeals in those cases are still ongoing, with arguments about establishing a false positive rate and the possibility of having a "vanishing twin" being put forward by Hamilton.
During the Tour, riders will give 150 urine samples and 40 blood samples. The World Anti-Doping Agency has asked that samples be kept for three months following the Tour for possible later testing.
Get The Leadout Newsletter
The latest race content, interviews, features, reviews and expert buying guides, direct to your inbox!
Thank you for reading 5 articles in the past 30 days*
Join now for unlimited access
Enjoy your first month for just £1 / $1 / €1
*Read any 5 articles for free in each 30-day period, this automatically resets
After your trial you will be billed £4.99 $7.99 €5.99 per month, cancel anytime. Or sign up for one year for just £49 $79 €59
Join now for unlimited access
Try your first month for just £1 / $1 / €1